Liminatus Pharma is well-positioned to become a leader on Guanylyl Cyclase C (GCC) CAR-T therapeutics with a promising focus towards a GCC vaccine.
The CAR-T therapeutics that we are developing utilize the GCC, which is an exclusive tumor marker for metastatic colorectal cancer developed by Dr. Scott A. Waldman’s team at Thomas Jefferson University Hospital. GCC has been validated as a vaccine target for the secondary prevention of metastases.
GCC CAR-T therapeutics
- Ability to target solid tumor cancers based on the discovery that unique GCC biomarkers are expressed in primary/metastatic tumor cells
- Technology developed using third-generation CAR-T cell therapeutics